PE20161067A1 - Analogos carba-nucleosidicos para tratamiento antiviral - Google Patents
Analogos carba-nucleosidicos para tratamiento antiviralInfo
- Publication number
- PE20161067A1 PE20161067A1 PE2016000564A PE2016000564A PE20161067A1 PE 20161067 A1 PE20161067 A1 PE 20161067A1 PE 2016000564 A PE2016000564 A PE 2016000564A PE 2016000564 A PE2016000564 A PE 2016000564A PE 20161067 A1 PE20161067 A1 PE 20161067A1
- Authority
- PE
- Peru
- Prior art keywords
- carba
- treatment
- nucleosidic
- antiviral treatment
- methyltetrahydrofuran
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000710781 Flaviviridae Species 0.000 abstract 2
- 108060004795 Methyltransferase Proteins 0.000 abstract 2
- FHOZPJTWYIPANB-NUBDZMHLSA-N (2r,3r,4r,5r)-2-(4-aminothieno[3,4-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1C1=C2N=CN=C(N)C2=CS1 FHOZPJTWYIPANB-NUBDZMHLSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a compuestos analogos carba-nucleosidicos de formula I donde R1, R2, R3, R4, R5 o R6 son H, CN, NO2, entre otros; R7 es H, entre otros; R8, R9 y R10 son H, halogeno, entre otros; X2 es O, S, entre otros. Son compuestos preferidos: (2R,3R,4R,5R)-2-(4-aminotieno[3,4-d]pirimidin-7-yl)-5-(hidroximetil)-3-metilltetrahidrofuran-3,4-diol; 2-amino-7-[(2R,3R,4R,5R)-3,4-dihidroxi-5-(hidroximetil)-3-metiltetrahidrofuran-2-il]tieno[3,4-d]pirimidin-4(3H)-ona, entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos inhiben ARN polimerasa dependiente de ARN de VHC (RdRp) de virus de la familia Flaviviridae, siendo utiles en el tratamiento de infecciones virales por Flaviviridae
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15124809P | 2009-02-10 | 2009-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161067A1 true PE20161067A1 (es) | 2016-10-23 |
Family
ID=42333309
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000758A PE20160858A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2011001464A PE20120257A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2016000564A PE20161067A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000758A PE20160858A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
| PE2011001464A PE20120257A1 (es) | 2009-02-10 | 2010-02-09 | Analogos carba-nucleosidicos para tratamiento antiviral |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8012942B2 (es) |
| EP (2) | EP2396340B1 (es) |
| JP (2) | JP5746638B2 (es) |
| KR (2) | KR101834707B1 (es) |
| CN (1) | CN102348713B (es) |
| AP (1) | AP2922A (es) |
| AU (3) | AU2010213873B2 (es) |
| BR (1) | BRPI1013643A2 (es) |
| CA (1) | CA2751277C (es) |
| CL (1) | CL2011001906A1 (es) |
| CO (1) | CO6420354A2 (es) |
| DK (1) | DK2396340T3 (es) |
| EA (1) | EA025085B1 (es) |
| ES (2) | ES2453078T3 (es) |
| HK (1) | HK1163108A1 (es) |
| HR (1) | HRP20140219T1 (es) |
| IL (1) | IL214396A (es) |
| MX (2) | MX345562B (es) |
| NZ (1) | NZ594370A (es) |
| PE (3) | PE20160858A1 (es) |
| PL (1) | PL2396340T3 (es) |
| PT (2) | PT2719701T (es) |
| SG (1) | SG173186A1 (es) |
| SI (1) | SI2396340T1 (es) |
| SM (1) | SMT201400056B (es) |
| UA (2) | UA112140C2 (es) |
| WO (1) | WO2010093608A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| CA2722177C (en) | 2008-04-23 | 2016-08-16 | Gilead Sciences, Inc. | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| TWI483950B (zh) | 2009-09-21 | 2015-05-11 | Gilead Sciences Inc | 用於製備１’－取代碳核苷類似物之方法及中間物 |
| ES2524398T3 (es) | 2010-07-19 | 2014-12-09 | Gilead Sciences, Inc. | Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros |
| AU2011280910B2 (en) | 2010-07-22 | 2015-07-09 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
| SG188223A1 (en) * | 2010-09-20 | 2013-04-30 | Gilead Sciences Inc | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013084165A1 (en) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
| WO2013118097A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| BR112014029115A8 (pt) | 2012-05-22 | 2018-04-03 | Idenix Pharmaceuticals Inc | Composto, composição farmacêutica, e, uso de um composto ou composição |
| ES2597757T3 (es) | 2012-05-25 | 2017-01-20 | Janssen Sciences Ireland Uc | Nucleósidos de uracilespirooxetano |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| EA030189B8 (ru) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | Аналоги 2'-хлоронуклеозидов для инфекции вгс |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| CN105814068B (zh) * | 2014-02-27 | 2017-08-04 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
| CN112209980B (zh) | 2015-03-06 | 2023-12-05 | 阿堤亚制药公司 | 取代的嘌呤核苷酸 |
| CA2984421C (en) * | 2015-05-01 | 2024-04-09 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| EP4088725A1 (en) | 2016-09-07 | 2022-11-16 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family |
| PT3577124T (pt) | 2017-02-01 | 2025-02-14 | Atea Pharmaceuticals Inc | Sal hemissulfato de nucleótido para o tratamento do vírus da hepatite c |
| CN116036112A (zh) | 2017-03-14 | 2023-05-02 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN117982682A (zh) | 2017-07-11 | 2024-05-07 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| KR20210121105A (ko) * | 2019-02-01 | 2021-10-07 | 얀센 바이오파마, 인코퍼레이트. | 항바이러스 뉴클레오시드 및 이의 유도체 |
| TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN118994170A (zh) | 2020-03-12 | 2024-11-22 | 吉利德科学公司 | 制备1'-氰基核苷的方法 |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
| AU2021331214B2 (en) | 2020-08-27 | 2024-01-04 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CN116568688A (zh) * | 2020-08-27 | 2023-08-08 | 吉利德科学公司 | 用于治疗病毒感染的化合物和方法 |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| KR20030005197A (ko) | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| EP2251015B1 (en) | 2000-10-18 | 2013-02-20 | Gilead Pharmasset LLC | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| JP3914156B2 (ja) * | 2001-01-22 | 2007-05-16 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| SG192409A1 (en) | 2004-09-14 | 2013-08-30 | Gilead Pharmasset Llc | 2-deoxy-2-fluoro-2-c-methyl-ribono lactones, and preparation thereof and 1,3-dioxolanes |
| KR20070100237A (ko) * | 2004-10-29 | 2007-10-10 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | 치료용 푸로피리미딘 및 티에노피리미딘 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| CA2672613A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| AU2008206406A1 (en) | 2007-01-12 | 2008-07-24 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2155758B1 (en) | 2007-05-10 | 2012-08-22 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
-
2010
- 2010-02-09 DK DK10704068.5T patent/DK2396340T3/en active
- 2010-02-09 PT PT131946055T patent/PT2719701T/pt unknown
- 2010-02-09 AP AP2011005818A patent/AP2922A/xx active
- 2010-02-09 PE PE2016000758A patent/PE20160858A1/es not_active Application Discontinuation
- 2010-02-09 MX MX2014007180A patent/MX345562B/es unknown
- 2010-02-09 KR KR1020177008719A patent/KR101834707B1/ko active Active
- 2010-02-09 MX MX2011008409A patent/MX2011008409A/es active IP Right Grant
- 2010-02-09 JP JP2011549324A patent/JP5746638B2/ja not_active Expired - Fee Related
- 2010-02-09 PT PT107040685T patent/PT2396340E/pt unknown
- 2010-02-09 ES ES10704068.5T patent/ES2453078T3/es active Active
- 2010-02-09 US US12/702,957 patent/US8012942B2/en active Active
- 2010-02-09 UA UAA201506736A patent/UA112140C2/uk unknown
- 2010-02-09 EP EP10704068.5A patent/EP2396340B1/en active Active
- 2010-02-09 AU AU2010213873A patent/AU2010213873B2/en not_active Ceased
- 2010-02-09 BR BRPI1013643A patent/BRPI1013643A2/pt active Search and Examination
- 2010-02-09 WO PCT/US2010/023586 patent/WO2010093608A1/en active Application Filing
- 2010-02-09 EA EA201190110A patent/EA025085B1/ru not_active IP Right Cessation
- 2010-02-09 KR KR1020117020990A patent/KR101724759B1/ko not_active Expired - Fee Related
- 2010-02-09 PE PE2011001464A patent/PE20120257A1/es active IP Right Grant
- 2010-02-09 CN CN201080011690.0A patent/CN102348713B/zh not_active Expired - Fee Related
- 2010-02-09 NZ NZ594370A patent/NZ594370A/en not_active IP Right Cessation
- 2010-02-09 PL PL10704068T patent/PL2396340T3/pl unknown
- 2010-02-09 SG SG2011054798A patent/SG173186A1/en unknown
- 2010-02-09 SI SI201030554T patent/SI2396340T1/sl unknown
- 2010-02-09 EP EP13194605.5A patent/EP2719701B1/en active Active
- 2010-02-09 CA CA2751277A patent/CA2751277C/en not_active Expired - Fee Related
- 2010-02-09 PE PE2016000564A patent/PE20161067A1/es not_active Application Discontinuation
- 2010-02-09 ES ES13194605.5T patent/ES2628842T3/es active Active
- 2010-09-02 UA UAA201110568A patent/UA110093C2/ru unknown
-
2011
- 2011-08-02 IL IL214396A patent/IL214396A/en not_active IP Right Cessation
- 2011-08-09 CL CL2011001906A patent/CL2011001906A1/es unknown
- 2011-08-26 CO CO11109501A patent/CO6420354A2/es active IP Right Grant
-
2012
- 2012-04-05 HK HK12103428.2A patent/HK1163108A1/xx unknown
-
2014
- 2014-03-10 HR HRP20140219AT patent/HRP20140219T1/hr unknown
- 2014-04-28 SM SM201400056T patent/SMT201400056B/xx unknown
- 2014-07-07 JP JP2014139374A patent/JP5951690B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 AU AU2015238785A patent/AU2015238785B2/en not_active Ceased
-
2017
- 2017-04-12 AU AU2017202413A patent/AU2017202413B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160858A1 (es) | Analogos carba-nucleosidicos para tratamiento antiviral | |
| PE20091424A1 (es) | Nucleosidos 2',4'-sustituidos como agentes antivirales | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral | |
| EA201500304A1 (ru) | Аналоги 2'-хлоро нуклеозидов для инфекции вгс | |
| PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR056850A1 (es) | MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA | |
| ECSP12012282A (es) | Fosforamidatos de nucleósido | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| PE20091727A1 (es) | Agentes terapeuticos antivirales | |
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| PE20160658A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos | |
| GT200200117A (es) | Derivados de nucleosidos | |
| PA8588501A1 (es) | Derivados antivirales de nucleósidos | |
| AR082068A2 (es) | Analogos de nucleosidos fluorados modificados | |
| EA200701850A1 (ru) | Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих | |
| CR8935A (es) | Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones | |
| CO6382185A2 (es) | Compuestos nucleosidos antivirales | |
| ECSP099319A (es) | Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus | |
| AR082937A1 (es) | Fosforamidatos de nucleosido | |
| EA201390141A1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| SV2005001919A (es) | Compuestos nucleosidos para el tratamiento de infecciones virales | |
| UY28110A1 (es) | Derivados de nucleosido antivirales | |
| CY1115086T1 (el) | Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη | |
| CY1116976T1 (el) | Κρυσταλλικο 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-δioξo-3,4-δiϋδpοπυριmiδιν-1-(2η)-υλ)-4-φθορο-3-υδροξυ-4-μεθυλτετραϋδροφουραν-2-υλ)μεθοξυ)(φαινοξυ)φωσφορυλ)αμινο)προπανοϊκο (s)-ισοπροπυλιο | |
| ECSP034699A (es) | Compuestos nucleosidos como inhibidores de polimerasa de arn viral dependiente de arn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |